SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001664710-22-000002
Filing Date
2022-01-31
Accepted
2022-01-31 08:02:51
Documents
14
Period of Report
2022-01-28
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K kros-20220128.htm   iXBRL 8-K 55652
2 EX-10.1 exhibit101coo.htm EX-10.1 87747
3 EX-99.1 exhibit991coo.htm EX-99.1 6485
  Complete submission text file 0001664710-22-000002.txt   324161

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT kros-20220128.xsd EX-101.SCH 1899
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT kros-20220128_lab.xml EX-101.LAB 26869
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT kros-20220128_pre.xml EX-101.PRE 14117
8 EXTRACTED XBRL INSTANCE DOCUMENT kros-20220128_htm.xml XML 13144
Mailing Address 99 HAYDEN AVENUE, SUITE 120 (BLD E) LEDGEMONT TECHNOLOGY CENTER LEXINGTON MA 02421
Business Address 99 HAYDEN AVENUE, SUITE 120 (BLD E) LEDGEMONT TECHNOLOGY CENTER LEXINGTON MA 02421 617-513-8774
Keros Therapeutics, Inc. (Filer) CIK: 0001664710 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39264 | Film No.: 22571382
SIC: 2834 Pharmaceutical Preparations